Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAT 4406F

Next Previous
Drug Profile

BAT 4406F

Alternative Names: BAT-4406F

Latest Information Update: 24 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bio-Thera Solutions
  • Class Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; B cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Neuromyelitis optica

Highest Development Phases

  • Phase III Neuromyelitis optica

Most Recent Events

  • 14 Jan 2025 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Neuromyelitis optica released by Bio-Thera Solutions
  • 01 Aug 2023 Phase-II/III clinical trials in Neuromyelitis optica in China (IV) (NCT06044350)
  • 03 Jul 2023 Phase-III clinical trials in Neuromyelitis optica (In the elderly, In adults) (IV) prior to July 2023 (Bio-Thera Solutions pipeline, July 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top